Entera Bio Ltd. Files 8-K on Warrants
Ticker: ENTX · Form: 8-K · Filed: Jan 10, 2025 · CIK: 1638097
| Field | Detail |
|---|---|
| Company | Entera Bio LTD. (ENTX) |
| Form Type | 8-K |
| Filed Date | Jan 10, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: warrants, disclosure, financials
Related Tickers: ENTX
TL;DR
Entera Bio Ltd. 8-K: Warrants exercisable at $5.85 per half share.
AI Summary
Entera Bio Ltd. filed an 8-K on January 10, 2025, reporting on financial statements and exhibits. The filing details warrants exercisable for half an Ordinary Share at an exercise price of $5.85 per share. The company is incorporated in Israel and listed on NASDAQ under ticker ENTXW.
Why It Matters
This filing provides details on outstanding warrants, which could impact future share dilution and the company's capital structure.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of financial information and exhibits, not indicating any immediate operational or financial distress.
Key Numbers
- $5.85 — Warrant Exercise Price (Price at which warrants can be exercised for Ordinary Shares.)
Key Players & Entities
- Entera Bio Ltd. (company) — Registrant
- January 10, 2025 (date) — Date of earliest event reported
- $5.85 (dollar_amount) — Exercise price per Ordinary Share for warrants
- ENTXW (company) — NASDAQ ticker symbol
FAQ
What type of financial information is being reported in this 8-K?
This 8-K reports on financial statements and exhibits.
What is the exercise price of the warrants mentioned?
The warrants are exercisable at an exercise price of $5.85 per Ordinary Share.
For how much of an Ordinary Share is each warrant exercisable?
Each warrant is exercisable for half of an Ordinary Share.
What is the ticker symbol for Entera Bio Ltd. on NASDAQ?
The ticker symbol is ENTXW.
In which jurisdiction is Entera Bio Ltd. incorporated?
Entera Bio Ltd. is incorporated in Israel.
Filing Stats: 470 words · 2 min read · ~2 pages · Grade level 10.1 · Accepted 2025-01-10 16:06:21
Filing Documents
- zk2532537.htm (8-K) — 31KB
- exhibit_5-1.htm (EX-5.1) — 16KB
- image00004.jpg (GRAPHIC) — 7KB
- 0001178913-25-000080.txt ( ) — 236KB
- entx-20250110.xsd (EX-101.SCH) — 5KB
- entx-20250110_def.xml (EX-101.DEF) — 18KB
- entx-20250110_lab.xml (EX-101.LAB) — 27KB
- entx-20250110_pre.xml (EX-101.PRE) — 20KB
- zk2532537_htm.xml (XML) — 7KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 5.1 Opinion of Herzog Fox & Neeman. 23.1 Consent of Herzog Fox & Neeman (included in Exhibit 5.1 hereto). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ENTERA BIO LTD. Date: January 10, 2025 By: /s/ Miranda Toledano Name: Miranda Toledano Title: Chief Executive Officer